Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, November 25, 2014
 
Register | Sign in
Home Page > Application Notes
  Application Notes
Scientific News
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Proteomics for Systems Toxicology
MS-based proteomics is maturing into a robust technology for the measurement of proteome-wide exposure effects.
How A Mutant Gene Can Cause Deafness
Scientists at The Scripps Research Institute (TSRI) have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies.
Developing a Noninvasive Test for Endometriosis
UCSF researchers identify patterns of genetic activity that could help in early detection of disorder.
Precisely Off The Mark
Possible cause discovered for failure of targeted liver cancer therapies.
Powerful Method To Speed Cancer Drug Discovery Unveiled
The new method lets researchers identify weak and previously undetectable interactions between proteins inside living cells.
Brain-dwelling Worm in UK Man's Head Sequenced
Tapeworm removed from UK resident's brain reveals genetic secrets of an elusive Far East parasite.
Researchers Tease Out Glitches in Immune System's Self-Recognition
A new study revises understanding of how the process works and sheds light on autoimmune disease.
Crowdsourcing Science To Beat Psa
Scientists are hoping that crowdsourcing knowledge from the international science community will help them find the answer to a lethal kiwifruit disease.
Breakthrough in Managing Yellow Fever Disease
UC Riverside-led research could lead to antiviral therapeutics and better diagnostics to prevent spread of potentially fatal viral infection.
Scroll Up
Scroll Down

Efficient Delivery of Thermo Scientific Dharmacon SMARTpool siRNA Reagents in Difficult-to-Transfect Cell Lines Using Nucleofector® 96-well Shuttle® System
Bookmark and Share
Lonza


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv